Information Provided By: 
Fly News Breaks for August 18, 2017
AZN, TSRO
Aug 18, 2017 | 07:36 EDT
Credit Suisse analyst Alethia Young believes AstraZeneca's (AZN) broad label news yesterday for Lynparza likely lifted an overhang for both Tesaro (TSRO) and Clovis Oncology (CLVS). Shares of both Tesaro and Clovis are reflecting "very little to no M&A value" at current levels, Young tells investors in a research note. She lowered her price target for Tesaro to $190 from $198 and keeps an Outperform rating on the name.
News For TSRO;AZN From the Last 2 Days
AZN
Apr 26, 2024 | 11:59 EDT
AZN
Apr 26, 2024 | 11:37 EDT
AZN
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.
